BrightSpring Health Services, Inc. Common Stock Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Appreciation and Performance: Grateful to teammates for high-quality care. Second quarter results exceeded expectations with revenue and adjusted EBITDA both up ~30% year-over-year.
• Business Segments: Pharmacy Solutions saw strong growth in Specialty, Infusion, and Home & Community Pharmacy. Provider Services showed growth in home health, rehab, and personal care.
• Quality and Satisfaction: High patient and customer satisfaction scores across all service lines, e.g., home health 90% of locations with 4+ stars, hospice top 5% ranked with high quality index, rehab 99% patient satisfaction.
• Industry Topics: Discussion on CMS rates for hospice (adequate) and home health (not adequate) but expectation of future rate improvements. Views on pharmacy regulatory topics like pharma tariffs and IRA, emphasizing patient care and access.

Segment Performance

• Pharmacy Solutions: Revenue of $2.8 billion in Q2, up 32% year-over-year. Adjusted EBITDA increased 32%. Specialty and Infusion revenue grew 39%, with specialty scripts up 38% and 131 licensed drug deliveries (LDDs) including 5 launches in Q2. Home & Community Pharmacy revenue grew 11% driven by increased script volumes and customer wins.
• Provider Services: Revenue of $358 million in Q2, up 11% year-over-year. Home health care (50% of Provider revenue) grew 17%, rehab care (20%) grew 9%, personal care (30%) grew 4%. Segment adjusted EBITDA grew 11% with a margin of 15.8%.

Guidance

• Revised Guidance: Increased total revenue guidance to $12.2 billion to $12.6 billion and adjusted EBITDA guidance to $590 million to $605 million for 2025. Driven by improved pharmacy revenue outlook, procurement and efficiency initiatives, strong provider performance, and favorable rate developments.

Risks

• Regulatory Risks: Uncertainties around home health rate finalization, potential policy impacts on pharmacy pricing, and ongoing FTC review of Community Living divestiture.

Question and Answer

• Q: Infusion performance and growth expectations A: New leadership in Infusion, strong quarter, expecting continued growth with focus on acute and chronic therapies.
• Q: Back half guidance uplift A: Continued momentum across company, efficiency initiatives, favorable rate developments, and broad-based growth.
• Q: M&A pipeline A: Focus on low-multiple tuck-in acquisitions, waiting on divestiture outcomes, aiming for debt reduction and leverage target.
• Q: Home health rule impact A: Modest impact currently, but expected rate improvements in future with measured growth strategy.
• Q: Specialty Pharmacy growth sustainability A: Long-term growth due to strong service model, quality, and relationships, with continued investments.
• Q: Generic utilization and procurement A: Focus on generic utilization, robust procurement team driving efficiencies across all spend areas.
• Q: Value-based contracts and hospice build-out A: Progressing value-based contracts, hospice acquisition (Haven) performing well ahead of expectations.